Terpolymers and their use in pharmaceutical dosage forms

US12016926B2 · kind B2 · utility

Assignee

• BASF SE

Inventors

• Ferdinand Paul Brandl · Ludwigshafen, DE
• Theo Smit · Heidelberg, DE
• Felicitas Guth · Neustadt, DE
• Karl Kolter · Ludwigshafen am Rhein, DE
• Maximilian Angel · Mutterstadt, DE
• Frank Schmidt · Lisle, US

Key dates

• Filing date: Dec 7, 2018
• Grant date: Jun 25, 2024
• Expiry date: Sep 28, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C08F226/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Terpolymer, wherein 20 to 35% by weight of the structural units are derived from acrylic acid, 45 to 60% by weight of the structural units from a hydrophobic methacrylate selected from a group consisting of isopropyl methacrylate, tert-butyl methacrylate and cyclohexyl methacrylate and 15 to 40% by weight of the structural units from a third olefinic monomer selected from the group consisting of N-vinyl lactam, hydroxy ethyl methacrylate and phenoxyethyl acrylate with the proviso that the total amount of structural units derived from the three monomer groups adds up to 100% by weight, and the use of the terpolymers as crystallization inhibitors in pharmaceutical dosage forms for inhibiting the recrystallization in an aqueous environment of a human or animal body of an active ingredient.